Showing results (91-100 of 163) with videos related to

Sort By:
Pageof 17
Proceedings of the National Academy of Sciences of the United States of America|May 13, 2009
RNAi screen for rapid therapeutic target identification in leukemia patientsJeffrey W Tyner, Michael W Deininger, Marc M Loriaux, et al.
Leukemia|May 12, 2018
Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashionWilliam L Heaton, Anna V Senina, Anthony D Pomicter, et al.
Blood|November 21, 2007
RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemiaJeffrey W Tyner, Denise K Walters, Stephanie G Willis, et al.
Blood|June 4, 2010
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinibDaniel W Sherbenou, Oliver Hantschel, Ines Kaupe, et al.
Cancer Research|July 31, 2010
MET receptor sequence variants R970C and T992I lack transforming capacityJeffrey W Tyner, Luke B Fletcher, Ellen Q Wang, et al.
Leukemia|May 16, 2020
Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanismsAmi B Patel, Anthony D Pomicter, Dongqing Yan, et al.
Cancer Chemotherapy and Pharmacology|April 24, 2013
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignanciesDaryl Sonnichsen, David J Dorer, Jorge Cortes, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 28, 2008
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinibThomas O'Hare, Christopher A Eide, Jeffrey W Tyner, et al.
Blood|September 13, 2011
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemiaThomas O'Hare, Matthew S Zabriskie, Christopher A Eide, et al.
Journal of Cancer Research and Clinical Oncology|April 17, 2019
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemiaJorge E Cortes, Carlo Gambacorti-Passerini, Michael W Deininger, et al.
Pageof 17